SH PHARMA (02607) announced its financial results for the 2025 fiscal year. The company reported total operating revenue of RMB 283.580 billion, representing a year-on-year increase of 3.03%. Revenue from the pharmaceutical manufacturing segment reached RMB 24.522 billion, up 3.33% compared to the previous year, while revenue from the pharmaceutical commercial segment amounted to RMB 259.058 billion, an increase of 3.00%. Net profit attributable to equity shareholders of the company was RMB 5.725 billion, marking a significant rise of 25.74% year-on-year. This increase in net profit was primarily due to a one-time special gain resulting from a change in the accounting treatment for Hutchison Whampoa China Meditech Limited, which was reclassified from an investment accounted for using the equity method to a subsidiary. Excluding this and other one-time special gains and losses, the adjusted net profit attributable to shareholders was RMB 4.721 billion, reflecting a decrease of 5.56% compared to the prior year. During the reporting period, the industrial segment contributed a profit of RMB 2.039 billion, the commercial segment contributed a profit of RMB 3.457 billion, and major equity investees contributed a profit of RMB 325 million. In the area of new drug research and development, the Class 1 innovative drug Sitagliptin Maleate Tablets was successfully approved for market launch, offering a new treatment option for over 300 million patients with primary hypertension in China and marking a significant milestone in the company's recent innovative development efforts. A highly humanized global innovative anti-CD20 antibody drug, B001 Injection, for the treatment of Neuromyelitis Optica Spectrum Disorders, has completed primary endpoint analysis in its pivotal study. Shenqi Sherong Pill, a Class 1.1 traditional Chinese medicine new drug for Cervical Spondylotic Myelopathy, has completed the withdrawal of all cases from its Phase III clinical trial. The chemical drug Class 1 new drug SHPL-49 Injection for the treatment of acute ischemic stroke and SRD4610 (Huoling Shengji Granules) for the treatment of Amyotrophic Lateral Sclerosis are steadily progressing through Phase III clinical trials, indicating continuous optimization of the company's pipeline. Positive progress has also been made in the new field of cell and gene therapy, which is expected to inject new momentum into future innovative development. Regarding the construction of an innovation ecosystem, the company remains committed to aggregating resources from industry, academia, research, healthcare, and capital, and is accelerating the development of its "One Academy, Four Institutes" framework. By internally strengthening technology platforms for peptides, macromolecules, small molecules, and small nucleic acids, and externally deepening collaborations with national key laboratories and research institutions such as Shanghai Jiao Tong University, the company is continuously solidifying its integrated internal and external R&D management system. Furthermore, leveraging Shanghai's forefront position, the company is attracting high-quality enterprises and institutions, building bridges and providing continuous support in areas such as equity financing and policy support, collectively fostering an open-source and dynamic innovation ecosystem.
Comments